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Eukaryotic cells release different types of extracellular vesicles (EVs) including exosomes,
ectosomes, and microvesicles. Exosomes are nanovesicles, 30–200 nm in diameter,
that carry cell- and cell-state-specific cargo of proteins, lipids, and nucleic acids,
including mRNA and miRNA. Recent studies have shown that central nervous system
(CNS)-derived exosomes may carry amyloidogenic proteins and facilitate their cell-to-cell
transfer, thus playing a critical role in the progression of neurodegenerative diseases, such
as tauopathies and synucleinopathies. CNS-derived exosomes also have been shown to
cross the blood-brain-barrier into the bloodstream and therefore have drawn substantial
attention as a source of biomarkers for various neurodegenerative diseases as they can
be isolated via a minimally invasive blood draw and report on the biochemical status
of the CNS. However, although isolating specific brain-cell-derived exosomes from the
blood is theoretically simple and the approach has great promise, practical details are of
crucial importance and may compromise the reproducibility and utility of this approach,
especially when different laboratories use different protocols. In this review we discuss
the role of exosomes in neurodegenerative diseases, the usefulness of CNS-derived
blood exosomes as a source of biomarkers for these diseases, and practical challenges
associated with the methodology of CNS-derived blood exosomes and subsequent
biomarker analysis.
Keywords: biomarker, exosome, extracellular vesicle (EV), neurodegenerative diseases, Alzheimer’ disease,
Parkinson’s and related diseases, ALS
INTRODUCTION
Eukaryotic cells release a variety of extracellular vesicles (EVs), including microvesicles, ectosomes,
oncosomes, and exosomes. EVs can be shed directly from the plasmamembrane, e.g., ectosomes, or
can be released upon fusion of multivesicular bodies (MVBs) with the plasmamembrane (Colombo
et al., 2014; Coleman and Hill, 2015; Lööv et al., 2016). Exosomes are formed via the latter process
by the inward budding of the endosomal membrane, creating MVBs that contain intralumenal
vesicles (ILVs). The formation of ILVs is regulated tightly and inmany cases depends on endosomal
sorting complex required for transport (ESCRT) proteins, and on tetraspanins, including CD9,
CD63, and CD81. Alternatively, ILVs can form by ESCRT-independent mechanisms, e.g., by a
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process mediated by ceramides (van Niel et al., 2011; Perez-
Hernandez et al., 2013; Colombo et al., 2014; Thompson
et al., 2016). Fusion of MVBs with the plasma membrane
leads to the release of ILVs as exosomes, ranging from
30 to 200 nm in diameter (Paulaitis et al., 2018), into the
extracellular space where they can be taken up by recipient
cells (Figure 1; Coleman and Hill, 2015; Lööv et al., 2016;
Thompson et al., 2016). The precise details of the uptake
mechanisms of exosomes into recipient cells are not known. In
general, exosomes can be taken up by non-specific endocytotic
mechanisms, such as macropinocytosis and micropinocytosis,
or by more specific, receptor-dependent pathways involving
integrins (Hoshino et al., 2015), proteoglycans (Christianson
et al., 2013), T cell immunoglobulins, and mucin-domain-
containing protein 4 (Tim4) (Miyanishi et al., 2007). Moreover,
exosomes can fuse directly with the plasma membrane releasing
their cargo into the cytosol of the recipient cell (Figure 1;
Montecalvo et al., 2012; Mathieu et al., 2019).
Transmission electron microscopy (TEM) images of
negatively stained exosomes initially indicated a cup-shaped
morphology, yet later cryo-electron microscopy images of
unfixed exosomes, including in a study by Banizs et al.,
comparing negative-stain EM and unstained cryo-EM of the
same exosome preparation, showed a spherical shape, suggesting
that the cup-shaped morphology might have resulted from the
fixation process in conventional TEM (Figure 2; Théry et al.,
2006; Raposo and Stoorvogel, 2013; Banizs et al., 2014).
Exosomes are produced and released by virtually all cell
types, including different brain cells, such as neurons, astrocytes,
microglia, and oligodendrocytes (Potolicchio et al., 2005; Fauré
et al., 2006; Krämer-Albers et al., 2007; Bianco et al., 2009; Dutta
et al., 2018; Goetzl et al., 2018; Xia et al., 2019). The nomenclature
used in the field is somewhat problematic. Isolation of pure
exosomes requires the use of methods such as a sucrose
cushion, a density gradient, size-exclusion chromatography,
or sequential ultracentrifugation and filtration steps and the
resulting vesicles must be characterized thoroughly for their
size, morphology, and biochemical characteristics (Lötvall et al.,
2014). However, because exosomes are the main type of vesicle
in preparations including other types of extracellular vesicles,
many authors have used the terms extracellular vesicles and
exosomes interchangeably. For simplicity, here we also use the
term “exosomes” inclusively when discussing papers that did not
go through the rigorous isolation protocols and characterization
needed to establish the identity of pure exosome preparation. The
reader should keep in mind that in many cases, the preparations
described as exosomes may contain also small amounts of other
extracellular vesicles.
Originally, exosomes were believed to be a disposal
mechanism of unwanted membranes and proteins during
the maturation process of reticulocytes into erythrocytes
(Pan, 1985). Recent studies have demonstrated that exosomes
have multiple additional roles including spreading various
proteins, DNA, mRNA, miRNA, and other non-coding RNAs
from cell to cell, often depending on the physiological state
of the parent cell (Valadi et al., 2007; Guescini et al., 2010;
Montecalvo et al., 2012; Cai et al., 2013; Budnik et al., 2016;
Sardar Sinha et al., 2018). In the central nervous system
(CNS), exosomes play critical physiological roles in intercellular
communication, maintenance of myelination, synaptic plasticity,
antigen presentation, and trophic support to neurons. Under
pathological conditions, especially in proteinopathies, there
is an increase in the use of this machinery for disposal of
accumulating, unwanted biomolecules (Krämer-Albers et al.,
2007; Antonucci et al., 2012; Lee et al., 2012; Budnik et al.,
2016; Goetzl et al., 2016; Thompson et al., 2016). In particular,
disposal of unwanted cellular components via exosomes occurs
to assist when other cellular clearance mechanisms, such as the
proteasome and autophagy-lysosome system, gradually fail in
eliminating aggregated amyloidogenic proteins (Alvarez-Erviti
et al., 2011; Ihara et al., 2012; Urbanelli et al., 2013; Fussi et al.,
2018; Miranda and Di Paolo, 2018). Under such conditions,
CNS-derived exosomes have been shown to be involved
in prion-like, cell-to-cell spread of amyloidogenic proteins,
including Aβ, tau, α-synuclein, and TDP-43 (Bellingham et al.,
2012; Vingtdeux et al., 2012; Feiler et al., 2015; Polanco et al.,
2016).
The role of exosomes in exporting amyloidogenic proteins
from brain cells in neurodegenerative proteinopathies has been
demonstrated in recent years by multiple groups who showed
that CNS-derived exosomes may be enriched in amyloidogenic
proteins, such as tau and hyperphosphorylated tau in Alzheimer’s
disease (AD) and other tauopathies (Clavaguera et al., 2009;
Liu et al., 2012; Vella et al., 2016), monomeric and oligomeric
amyloid β-protein (Aβ) in AD (Fiandaca et al., 2015; Sardar
Sinha et al., 2018), and α-synuclein in Parkinson’s disease (PD)
(Danzer et al., 2012).
Exosomes have been isolated successfully from human
serum and plasma (Caby et al., 2005; Fiandaca et al., 2015),
cerebrospinal fluid (CSF) (Vella et al., 2008), saliva (Ogawa
et al., 2008; Michael et al., 2010), and urine (Pisitkun et al.,
2004). Characterization of exosomes isolated from human
serum and plasma has demonstrated similarities in vesicle
size, shape, concentration, and presence of exosomal markers
suggesting that serum and plasma are equally useful for isolation
of blood exosomes (Soares Martins et al., 2018). Multiple
exosomal surface markers have been reported and are routinely
used to identify exosomes, including the tetraspanins CD9,
CD63, and CD81, ALG 2-interacting protein X (ALIX), tumor
susceptibility gene 101 protein (TSG101) and ESCRT proteins
(Théry et al., 2002; Dutta et al., 2015; Thompson et al., 2016).
Exosomes can cross the blood-brain-barrier (BBB) making them
a highly attractive source of biomarkers originating in the
CNS that could be isolated from the blood (Alvarez-Erviti
et al., 2011; Zheng et al., 2017). The ability to cross the
BBB in the opposite direction potentially can make exosomes
useful for delivering drugs and biomolecules into the brain
(Luan et al., 2017; Rashed et al., 2017) though this topic
is beyond the scope of our review. Rather, we focus on
exosomes that cross the BBB from the CNS into the blood
and discuss the role of CNS-derived exosomes in different
neurodegenerative disorders, biomarker opportunities, and the
technological challenges associated with isolation of CNS-derived
blood exosomes.
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FIGURE 1 | Biogenesis, secretion, and uptake of exosomes and their cargo. (1) Invagination of the cell membrane leads to the formation of early endosomes. (2)
ESCRT-0 recognizes and binds ubiquitynated proteins and further recruits ESCRT-I (including the exosomal marker TSG101) and ESCRT-II to this complex. (3)
ESCRT-III is a transient protein complex that plugs the inward budding vesicle to avoid the escape of the cargo during scission. Alix recruits deubiquitinases to
ESCRT-III, which remove ubiquitin from cargo proteins (Budnik et al., 2016). ESCRT proteins detach from the membrane and are released into the cytoplasm. (4) The
formed intralumenal vesicle contains the cargo protein and can either be (5) degraded in lysosomes or (6) secreted into the extracellular space. (7) The formation of
intralumenal vesicles can occur via ESCRT-independent pathways and is promoted by higher levels of ceramides in the lipid membrane (Budnik et al., 2016).
Exosomes released into the extracellular space can be taken up by recipient cells by endocytosis (8) or fusion with the plasma membrane (9) allowing the transport of
cargo between different cells and body parts.
FIGURE 2 | Electron micrographs of exosomes. Exosomes were isolated from cultured primary endothelial cells. Left: exosomes were stained with uranyl acetate and
embedded as whole mount preparations in methylcellulose. The image shows a cup-shaped morphology and heterogeneous sizes ranging from 30 to 100 nm. Right:
Exosomes were analyzed by cryoelectron microscopy without chemical fixation or contrasting. Exosomes appear as round membranous structures. Adapted from
panels B and C in Figure 1 of Banizs et al., © 2014, originally published in International Journal of Nanomedicine (Dovepress). https://doi.org/10.2147/IJN.S64267.
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ROLE OF CNS EXOSOMES IN
NEURODEGENERATIVE DISORDERS
Exosomes have been shown to play a crucial role in the
pathology of various neurodegenerative diseases, including
AD, PD, amyotrophic lateral sclerosis (ALS), frontotemporal
dementia (FTD), and prion diseases (Thompson et al., 2016;
Shi et al., 2019). In addition, multiple groups have begun using
exosomes as a source of biomarkers for these diseases. The most
common fluid biomarkers are listed in Table 1. Some of these
biomarkers already have been analyzed in exosomes in one or
more diseases, whereas others have been measured in biofluids
but not yet in exosomes. This section summarizes briefly the
current state of research into the role of exosomes in these
diseases whereas the subsequent section discusses their use as a
source of biomarkers originating in the CNS.
TABLE 1 | List of potential fluid biomarkers for diagnosis of neurodegenerative
diseases.
Disease Biomarker Biofluids References
AD Aβ42, pT181-tau,
pS396-tau,
total-tau
Neuronal
exosomes isolated
from blood, CSF
Tapiola et al.,
2009; Fiandaca
et al., 2015; Goetzl
et al., 2016;
Winston et al.,
2016; Jia et al.,
2019
PD α-synuclein, DJ-1 Neuronal
exosomes isolated
from blood, CSF
Shi et al., 2014;
Dutta et al., 2018;
Zhao et al., 2019
Prion diseases PrP, tau, 14-3-3 CSF
Otto et al., 1997;
Llorens et al.,
2018
FTD Aβ42, total tau,
pT181-tau,
pS396-tau, NfL
Neuronal
exosomes isolated
from blood, CSF
Irwin et al., 2013;
Fiandaca et al.,
2015;
Abu-Rumeileh
et al., 2018;
Goossens et al.,
2018
ALS TDP-43, NfL,
phospho-NfH
CSF, plasma,
serum Kasai et al., 2009;
Noto et al., 2011;
Boylan et al.,
2013; Hosokawa
et al., 2014;
Lehnert et al.,
2014; Lu et al.,
2015; Oeckl et al.,
2016
AD, Alzheimer‘s disease; Aβ42, Amyloid β-protein 1-42; CSF, Cerebrospinal fluid; FTD,
Frontotemporal dementia; NfH, Neurofilament heavy chain; NfL, Neurofilament light chain;
PD, Parkinson‘s disease; PrP, Prion protein; pS396-Tau, Tau phosphorylated at S396;
pT181-Tau, Tau phosphorylated at T181; TDP-43, transactive response DNA-binding
protein 43 kDa.
Alzheimer’s Disease
The pathology of AD is characterized by the aggregation of Aβ in
senile plaques and of hyperphosphorylated tau in neurofibrillary
tangles. Accumulation and spread of the latter lesion in
susceptible brain regions correlate with a progressive cognitive
decline (Rajendran et al., 2006; Guix et al., 2018). Different
roles of exosomes related to both Aβ and tau pathologies in
AD have been reported in several studies. Rajendran et al.
demonstrated that in HeLa and Neuroblastoma 2a (N2a) cells,
sequential cleavage of the amyloid β-protein precursor (APP)
by β-secretase occurs intracellularly in early endosomes, where
it may be directed subsequently to MVBs and secreted into the
extracellular space in exosomes after fusion of the MVB with
the plasma membrane. Possibly supporting this idea, the authors
showed that the exosomal marker Alix was enriched in the
vicinity of senile plaques in the AD brain, whereas the brain of a
patient with PD or of a healthy control subject stained negatively
for plaques and for Alix (Rajendran et al., 2006).
Other studies have shown that exosomes isolated from
neuronal cell cultures accelerated the aggregation of Aβ,
suppressed the formation of toxic Aβ oligomers, and facilitated
the uptake of Aβ by microglia (Yuyama et al., 2008, 2012). A
protective role of exosomes in AD pathogenesis was proposed
based on the finding that exosomes isolated from human CSF
or brain samples sequestered oligomeric Aβ in the brain (An
et al., 2013). The importance of the originating cell type for the
physiological effect of exosomes was highlighted by Dinkins et al.
who showed that exosomes isolated from astrocytes, in contrast
to neuronal exosomes, interfered with the uptake of Aβ in a
mixed glial cell culture. However, similar to neuronal exosomes,
astrocytic exosomes promoted Aβ aggregation (Yuyama et al.,
2012; Dinkins et al., 2014). Recently, it has been found that
N2a cells carrying the autosomal-dominant Swedish form of
APP (KM670/671NL) secreted exosomes containing Aβ and
C-terminal fragments of APP whereas cells expressing wild-
type APP secreted exosomes that contained the APP C-
terminal fragments but not Aβ. Furthermore, APP and its
C-terminal fragments were specifically sorted into exosomes
lacking the tetraspanin protein CD63, demonstrating that
neuroblastoma cells secrete distinct populations of exosomes
containing different cargos and targeting specific cell types
(Laulagnier et al., 2018).
Pathologic forms of tau have been shown to spread via
exosomes among different cells (Polanco et al., 2016). A
study by Clavaguera et al. demonstrated the spreading of
the frontotemporal-dementia-associated form P301S-tau from
mouse brain extracts to different brain regions after injection into
the hippocampus and the overlaying cerebral cortex of transgenic
mice expressing wild-type human tau (Clavaguera et al., 2009).
The authors did not comment on the potential involvement of
exosomes in the spread of tau pathology yet several subsequent
publications provided strong evidence for the presence of tau in
CNS-derived exosomes and the contribution of such exosomes
to the spread of the pathology. Tau and hyperphosphorylated
tau have been identified in exosomes isolated from human CSF
(Saman et al., 2012; Guix et al., 2018), human plasma and
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serum (Fiandaca et al., 2015; Guix et al., 2018), brain tissue of
transgenic rTg4510 mice (Polanco et al., 2016), and conditioned
medium of M1C cells (Saman et al., 2012). Further evidence
for a role of exosomes in the transmission of tau has been
provided by the findings that microglia secrete and phagocytose
exosomal tau and that inhibition of exosome synthesis reduced
tau propagation in mouse and cellular model systems (Asai et al.,
2015). Exosomes also may contribute to the interplay between Aβ
and tau in AD. In a recent study, Aulston et al. demonstrated that
treatment with EVs (presumablymostly exosomes), isolated from
induced pluripotent stem-cell (iPSc)-derived neuronal cultures
generated from a patient harboring the familial-AD-associated
A246E of presenilin-1, which increases the Aβ42/Aβ40 ratio,
induced tau phosphorylation in wild type C57BL/6 mouse brain
(Aulston et al., 2019). Taken together, there is already substantial
evidence for the contribution of exosomes to AD pathology,
both in spreading the pathology in the brain and potentially
in modulating Aβ aggregation. However, this is a developing
field and elucidating the precise mechanisms and implications of
exosome involvement in AD will require further investigation.
Parkinson’s Disease
The neuropathological hallmark of PD is the accumulation and
aggregation of α-synuclein in intracellular inclusions termed
Lewy bodies (LBs) and Lewy neurites. α-Synuclein also is the
main component of pathological aggregates in related disorders
called synucleinopathies, including dementia with Lewy bodies
and multiple system atrophy (Spillantini et al., 1998). Several
lines of evidence indicate participation of exosomes in the
intercellular spread of α-synuclein in the brain. Patients with
PD that received transplants of either embryonic nigral neurons
(Kordower et al., 2008) or fetal mesencephalic dopaminergic
neurons (Li et al., 2008) developed Lewy body-like inclusions
in these grafts over a period of 11–16 years, which stained
positive for α-synuclein. These finding might be attributed to
the prion-like spread of α-synuclein pathology from disease-
affected host neurons to the grafts, but also to other factors,
such as an unfavorable microenvironment, lack of appropriate
trophic signaling, or immune reactions (Kordower et al., 2008;
Li et al., 2008). Following up on these initial studies, Hansen et al.
explored intercellular α-synuclein transfer in disease propagation
using cellular co-culture model systems and transgenic mice.
They found that extracellular α-synuclein was taken up by
recipient cells via endocytosis and interacted with intracellular
α-synuclein. They also demonstrated the in-vivo transfer of α-
synuclein between host and grafted cells in a mouse model
overexpressing human α-synuclein, though this model was not
suitable for detecting the potential involvement of exosomes in
the transfer (Hansen et al., 2011).
Newly synthesized α-synuclein can be secreted rapidly via
unconventional exocytosis and has been found in the lumen of
cellular vesicles. Importantly, this intravesicular α-synuclein is
more prone to aggregation and is secreted from the cells (Lee,
2005). Proteasomal and mitochondrial dysfunction and other
cellular defects associated with PD pathogenesis lead to increased
secretion of monomeric and aggregated forms of α-synuclein
(Lee, 2005). Emmanouilidou et al. provided the first evidence
for exosomal secretion of α-synuclein in a calcium-dependent
manner in SH-SY5Y cells. Conditioned medium containing
exosomal α-synuclein has been shown to reduce the viability
of recipient neurons, suggesting that secretion of α-synuclein
contributed to the spreading of PD pathology (Emmanouilidou
et al., 2010). Additionally, lysosomal dysfunction is believed
to accelerate exosomal α-synuclein release and propagation to
surrounding cells (Alvarez-Erviti et al., 2011).
By using a novel protein-fragment-complementation assay,
Danzer et al. identified oligomeric α-synuclein species in
exosomes in the conditioned medium of human H4 neuroglioma
cells and primary cortical neurons. Moreover, they determined
that α-synuclein oligomers were present both on the outside and
the inside of exosomes, and suggested that α-synuclein could
be secreted through different pathways as it was found both
free and in association with exosomes (Danzer et al., 2012).
In the presence of exosomes, α-synuclein was more prone to
aggregation and exosome-associated α-synuclein was taken up
more efficiently by cells in culture than free α-synuclein, further
supporting a role for exosomes in the intercellular transfer of
α-synuclein (Danzer et al., 2012; Grey et al., 2015). A recent
study showed that phosphorylated α-synuclein concentration in
saliva exosomes was higher in patients with PD than in healthy
individuals. The authors also observed a higher abundance of
neuronal exosomes in the saliva of patients with PD, which they
speculated could reflect increased salivary secretion of exosomes
from neuronal endings in salivary glands (Rani et al., 2019).
Frontotemporal Dementia (FTD) and
Amyotrophic Lateral Sclerosis (ALS)
Frontotemporal dementia is a heterogeneous disorder that
causes progressive changes in behavior, language, memory,
executive control, and motor functions (Olney et al., 2017). It
is characterized pathologically by atrophy of the frontal lobe
and often involves accumulation of different forms of aberrantly
post-translationally modified and aggregated tau in the brain
of affected individuals. In addition, FTD can be characterized
pathologically by cellular inclusions of the transactive response
DNA-binding protein 43 kDa (TDP-43) (Turner et al., 2017), a
feature it shares with ALS, which is a distinct neurodegenerative
disease affecting motor neurons in the brain and spinal cord.
In fact, FTD and ALS appear to be on a spectrum and some
patients display mixed phenotypes of both diseases (Kawakami
et al., 2019). However, each disease also can present without
involvement of the other one and unlike TDP-43, which is shared
by both diseases, mutations in certain proteins are associated with
either FTD or ALS, but not both. For example, mutations in the
superoxide dismutase 1 (SOD1) gene lead to familial forms of
ALS but not FTD (Münch et al., 2011). The FTD-ALS clinical
spectrum correlates not only with TDP-43 inclusions in neuronal
and glial cells, but also with the observation that hexanucleotide-
repeat expansion of the C9orf72 gene can lead to ALS, FTD, or
a mixed clinical presentation of both diseases (Neumann et al.,
2006; Turner et al., 2017).
SOD1 was the first gene discovered to cause familial ALS
and the most studied cause of ALS. The presence of SOD1
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in exosomes secreted from motor-neuron-like NSC-34 cells
overexpressing human wild-type or mutant SOD1 provided the
first evidence for the secretion and cell-to-cell transmission
of SOD1 in the context of ALS (Gomes et al., 2007). Using
a similar cell model, misfolded, mutant, or wild-type human
SOD1 was shown to be transmitted between cells both as
free protein aggregates and through exosomal transport. In
addition, misfolding of human, wild-type SOD1 was propagated
in HEK293 cells via exosomes in conditioned media over
several passages and was transferred to cultured transgenic
mouse primary spinal cord neurons expressing human wild-
type SOD1 (Grad et al., 2014). Immunoelectron microscopy
using the misfolded-SOD1-specific antibody 3H1 (Pickles et al.,
2016; Atlasi et al., 2018) demonstrated that the majority of
SOD1 aggregates were present on the exterior of exosomes
isolated from the conditioned medium of cultured NSC-34 cells
(Grad et al., 2014).
Like SOD1, TDP-43 might be secreted in exosomes,
facilitating a prion-like spread of its misfolded species, though
to our knowledge, this has not yet been demonstrated
directly. Treatment of SH-SY5Y cells expressing TDP-43 with
brain extracts of buffer-insoluble proteins from patients with
ALS showed that the TDP-43 concentration was increased
significantly in exosomes isolated from the conditioned medium
compared to untreated cells, whereas the concentration level of
the exosomal marker CD63 did not differ between the fractions
suggesting that there was no change in exosome concentration
(Nonaka et al., 2013). A study by Feiler et al. used a protein-
complementation assay allowing the researchers to quantify
TDP-43 in HEK-293 cells. Western blot analysis showed the
presence of myc-tagged exogenous and endogenous TDP-43
in exosomes of cells transfected with myc-TDP-43. The study
showed that exosomal TDP-43 was taken up preferentially by
recipient cells and exerted higher toxicity than free TDP-43
(Feiler et al., 2015).
A study by Iguchi et al. provided further support for exosomal
transport of TDP-43 using exosomes from the cell-culture
medium of N2a cells. Cells expressing mutant forms of human
TDP-43 or a fragment thereof secreted the respective protein
forms in their exosomes. TDP-43 also was detected in purified
exosomes from primary cortical neurons of transgenic C57BL/6
mice expressing human TDP-43A315T but not from primary
astrocytes or microglia (Iguchi et al., 2016). The pathological
relevance of exosomal TDP-43 was highlighted by the presence of
TDP-43 in exosomes isolated from frozen post-mortem temporal
cortices of patients who died of sporadic ALS, in which TDP-43
concentration levels were increased compared to exosomes from
brains of healthy controls. Treatment of N2a cells overexpressing
human TDP-43 with GW4869 or siRNA silencing Rab27A to
reduce exosome secretion (Ostrowski et al., 2010) resulted in
increased intracellular levels of insoluble TDP-43 aggregates
(Iguchi et al., 2016). The studies presented above suggest that
TDP-43 is secreted via exosomes in the human brain and that
the exosomes are involved in the spread of TDP-43 pathology,
common to ALS and FTD, yet a conclusive demonstration of
these processes is still not available.
Prion Diseases
Transmissible prion encephalopathies, such as Creutzfeldt-Jakob
disease, scrapie, and bovine spongiform encephalopathy are
characterized by misfolding of the normal prion protein PrPc
into the aggregation-prone form PrPSc (Prusiner, 1982, 1991).
The first suggestion of an association of misfolded prion
protein with exosomes came from a ME7 scrapie-infected
mouse model in which PrPSc was identified in late-endosome-
like organelles from brain homogenates, which were obtained
by sequential centrifugation steps using a Nycodenz R© density
gradient. Analysis of these fractions by dot blot, western blot, and
double-labeled immunogold electron microscopy identified the
endosome-lysosome markers cathepsin B, mannose 6-phosphate
receptor, ubiquitin-protein conjugates, and β-glucuronidase
(Arnold et al., 1995). Because ILVs, the direct precursors of
exosomes, are formed in late endosomes (Stoorvogel et al., 2002),
the presence of PrPSc in these organelles may suggest a possible
localization of PrPSc in exosomes.
Based on multiple analysis methods, including western blot,
mass spectrometry, and morphological analysis, a later study
found strong evidence supporting this possibility. PrPc and PrPSc
were found to be actively released into the extracellular space by
PrP-expressing Rov cells before and after infection with sheep
PrPSc. Importantly, the study showed that exosomes containing
PrPSc were infectious to other cells, suggesting a contribution of
exosomes to the intercellular spread of prions in-vivo (Fevrier
et al., 2004). Further support for this hypothesis came from
studies reporting exosomal secretion of the endogenous prion
protein by cultured primary rat cortical cells (Fauré et al., 2006),
mouse hypothalamic neuronal GT1-7 cells (Vella et al., 2007),
and mouse N2a cells (Alais et al., 2008; Veith et al., 2009).
Additionally, exosomes derived from these cells were shown to
introduce prions into uninfected recipient cells (Vella et al., 2007;
Alais et al., 2008) and induce prion disease when inoculated
in mice (Vella et al., 2007). The relationship between exosome
release and intercellular prion transport was investigated also
by Guo et al. who observed that stimulation of exosome release
by treatment with the ionophore monensin (Savina et al., 2003)
led to an increase in prion infectivity, whereas inhibition of
exosome release using GW4869 (Guo et al., 2015) decreased
prion transmission between rabbit kidney epithelial (RK13) and
mouse GT1-7 cells (Guo et al., 2016).
In contrast to other neurodegenerative disorders, wherein
only a small fraction of the offending proteins are released in
exosomes, exosomes may be a major pathway for the spread
of pathological proteoforms in prion diseases (Arellano-Anaya
et al., 2015; Stuendl et al., 2016). Arellano-Anaya et al. (2015)
showed that strains of PrPsc from three different species were
secreted into the culture medium of RK13 cells and were present
in fractions containing exosomal markers and at typical densities
of exosomes. Moreover, it was shown that these exosomal prion
proteins retained their infectivity (Arellano-Anaya et al., 2015).
Pan et al. observed that prion proteins were secreted in exosomes
upon inhibition of cyclophillins by the immunosuppressive agent
cyclosporine A, which usually leads to an accumulation of
aggregated PrPsc and its deposition in aggresomes in N2a and
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Chinese hamster ovary cells (Pan et al., 2018). The presented
studies strongly indicate that different prion protein species are
secreted via exosomes and therefore contribute, possibly to a
high extent, to the spread of the misfolded, pathogenic protein
in prion diseases.
CNS-DERIVED EXOSOMES AS A SOURCE
OF BIOMARKERS FOR
NEURODEGENERATIVE DISEASES
Blood biomarkers are highly sought-after in the field of
neurodegenerative diseases. They offer important advantages
relative to expensive imaging modalities or the invasive lumbar
puncture required for analysis of CSF biomarkers. However,
drawbacks such as inconsistent results from different research
groups and weak or non-existent correlation with disease severity
or with CSF-derived or imaging biomarkers have hampered
progress in this direction (Mehta and Adler, 2016; Lashley et al.,
2018; Zhao et al., 2019). The relatively poor performance of
blood-based biomarkers reflects the disconnect between the brain
biochemistry and the blood composition, which is maintained
by the BBB to protect the brain. As CNS-derived exosomes can
cross the BBB into the blood and can be isolated from the blood,
measurement of biomarkers in them offers an attractive solution
for these issues.
The groups of Zhang at University of Washington, Seattle
and Goetzl at University of California, San Francisco have
pioneered this field establishing isolation protocols for
neuronal exosomes, which were used as a novel source for
neurodegenerative-disease biomarkers. Neuronal exosomes
were obtained by immunoprecipitation using antibodies
targeting the neuronal marker proteins NCAM or L1CAM
(see section Isolation of CNS-Derived Blood Exosomes).
NCAM is a neuronal cell adhesion protein that belongs to the
immunoglobulin superfamily and is involved in cell-cell and
cell-matrix interactions. L1CAM is an axonal glycoprotein that
plays an important role in nervous-system development and its
mutations cause neurological syndromes known as CRASH.
Using this methodology, Fiandaca et al. (2015) determined the
levels of total tau, pT181-tau, pS396-tau and Aβ42 in neuronal
exosomes in a cohort comprising patients with AD, patients
with FTD, and matching cognitively normal control subjects.
They found significantly higher levels of all four biomarkers
in patients with AD and of pT181-tau and Aβ42 in patients
with FTD compared to healthy controls. Impressively, their
final model classified 96.4% of patients with AD and 87.5%
of patients with FTD correctly and predicted the development
of AD up to 10 years before the onset of clinical symptoms
(Fiandaca et al., 2015).
Further analysis of neuronal exosomes obtained from
the same cohort, demonstrated that levels of cathepsin D,
LAMP-1, and ubiquitinated proteins, which are involved in
the proteasomal and lysosomal degradation pathways, were
significantly higher in patients with AD than in those with
FTD. Similar to their initial study, the authors found that the
concentration levels of the investigated proteins in neuronal
exosomes from patients with AD were significantly distinct from
those in age- and sex-matched healthy controls up to 10 years
before the diagnosis (Goetzl et al., 2015). The results suggested
that neuronal lysosomal dysfunction is an early event in the
development of AD and may be useful as a predictive biomarker
in prospective studies.
A following study by the Rissman group found that plasma-
derived neuronal exosomal levels of pT181-tau, pS396-tau,
and Aβ42 were increased, whereas the post-synaptic protein
neurogranin and repressor element 1-silencing transcription
factor (REST) levels were decreased in patients with AD or with
mild cognitive impairment (MCI) converting to AD compared to
normal subjects and patients with stableMCI that did not convert
to AD (Winston et al., 2016). These promising results suggest that
alterations of these neuronal-exosomal biomarkers could predict
the conversion fromMCI to AD.
An adaptation of the original procedure for isolation of
neuronal exosomes allowed Goetzl et al. to enrich astrocyte-
derived exosomes from plasma and subsequent analysis of
biomarkers in these exosomes (Goetzl et al., 2016). Astrocyte-
derived exosomes from patients with AD, patients with FTD,
and healthy controls showed up to 20-fold higher levels of β-
site amyloid β-protein precursor-cleaving enzyme 1, γ-secretase,
Aβ42, soluble APPα and APPβ, glial-derived neurotrophic factor,
pT181-tau, and pS396-tau compared to the concentrations
measured in neuronal exosomes. Moreover, concentration levels
of Aβ42 in astrocytic exosomes were lower in AD samples
compared to the concentrations in healthy control samples,
whereas pT181-tau, pS396-tau, and Aβ42 concentration in
neuronal exosomes were significantly higher than in the control
samples (Goetzl et al., 2016). In a recent study, Rissman’s group
showed that plasma-derived neuronal and astrocytic exosomes
from patients with mild traumatic brain injury (mTBI) contained
high levels of Aβ42 and low levels of neurogranin compared
to healthy individuals with no history of TBI, suggesting that
injury-associated proteins in these exosomes could be used as
biomarkers for mTBI (Winston et al., 2019).
The Zhang group analyzed α-synuclein in neuronal exosomes
from a large cohort of 267 patients with PD and 215 healthy
controls and found that α-synuclein concentrations in the
isolated exosomes were higher in the PD group compared to
the control group. Although the diagnostic performance of
neuronal exosomal α-synuclein wasmoderate (receiver operating
characteristic (ROC) analysis AUC = 0.654, sensitivity = 70.1%,
specificity = 52.9%), a significant cross-sectional correlation of
neuronal exosomal α-synuclein was found with disease severity
(Shi et al., 2014), suggesting that if a similar correlation were
observed longitudinally, this biomarker could be useful for
measuring PD progression and outcome measures of clinical
trials. In a follow-up study, the same group demonstrated that
tau protein levels in neuronal exosomes were elevated in patients
with PD but not in patients with AD (Shi et al., 2016). In a
longitudinal study, Wang et al. tested the utility of plasma α-
synuclein and CNS-derived exosomal α-synuclein at baseline
and in 2-year follow-up samples in a cohort comprising 256
individuals who might be at risk of PD. Their data showed that
an increase in plasma α-synuclein at baseline and at follow-up
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could predict progression of cognitive decline in a subgroup of
people with an increased PD risk, evidenced by hyposmia and
reduced dopamine transporter imaging. In contrast, a decrease
of α-synuclein in exosomes was associated with worsening of
cognitive performance (Wang et al., 2018).
Recently, the protocol developed by Goetzl et al. was used by
another group to determine the levels of DJ-1 and α-synuclein
in neuronal exosomes from 39 patients with PD and 40 healthy
controls (Zhao et al., 2019). Both, DJ-1 and α-synuclein were
significantly higher in neuronal exosomes from patients with
PD than in those from healthy controls whereas no significant
differences were observed in total plasma, in agreement with the
previous study by Shi et al. (2014). As in the previous study, ROC
analysis yielded only a moderate discrimination between patients
with PD and healthy controls even when both biomarkers were
combined (Zhao et al., 2019).
In another new study, Aβ42, total tau, and pT181-tau were
analyzed in two cohorts consisting of patients with AD, patients
with amnestic MCI (aMCI), and healthy controls (Jia et al.,
2019). The study included a discovery stage cohort comprising
28 patients with AD, 25 patients with aMCI, and 29 healthy
controls, and a larger validation cohort consisting of 73 patients
with AD, 71 patients with aMCI, and 72 healthy controls. The
authors compared the biomarker concentration levels in the
neuronal exosomes to the concentration of the same biomarkers
in the CSF of all subjects. The data in both the discovery and
validation cohorts showed that all three assessed biomarkers—
Aβ42, total tau, and pT181-tau in neuronal exosomes were
highest in patients with AD, significantly lower in patients with
aMCI, and lowest in healthy controls. Encouragingly, the level
of each exosomal biomarker showed a strong correlation with
the respective CSF biomarker, suggesting that the measurement
of these biomarkers in the neuronal exosomes could replace
CSF analysis (Jia et al., 2019). A comprehensive summary of the
studies described in this section is shown in Table 2.
These studies demonstrate the potential of CNS-derived blood
exosomes as a source of diagnostic, prognostic, and progression
biomarkers for neurodegenerative diseases. In addition to blood
products, exosomes obtained from other biofluids, such as CSF
and saliva, also have been used for diagnostic purposes (Yoo
et al., 2018; Cao et al., 2019). Obtaining saliva from patients
is less invasive than obtaining blood and saliva is easier to
process because it does not coagulate. However, as a source
of biomarkers in neurodegenerative (and systemic) diseases,
saliva has been studied much less than plasma or serum, likely
because variability and risk of contamination in saliva compared
to blood are higher (Han et al., 2018; Cao et al., 2019). In
contrast, the fidelity of biomarkers measured in CNS-derived
blood exosomes as representing biochemical changes in the
CNS has been found to be similar to that of CSF biomarkers,
suggesting that the same level of confidence can be achieved
using a substantially less invasive procedure. This is important in
particular for measurement of treatment efficacy in clinical trials
where multiple tests often are required during the trial. Similar
to CSF biomarker studies, the data also suggest that biomarker
panels likely will provide better diagnostic or prognostic power
than single biomarkers (Fiandaca et al., 2015; Goetzl et al., 2016;
Shi et al., 2016; Winston et al., 2016). A particular advantage of
biomarker analysis in CNS-derived blood exosomes compared
to CSF is the ability to compare the biomarkers in exosomes
originating in different cell types.
ISOLATION OF CNS-DERIVED BLOOD
EXOSOMES
Numerous methods for isolation of exosomes have been
reported, including protocols based on ultracentrifugation,
filtration, precipitation, immuno-affinity capture, and
microfluidics arrays (Contreras-Naranjo et al., 2017; Doyle
and Wang, 2019; Zhang et al., 2019). However, only a minority
of the reported methods can yield a sufficient number of
exosomes when starting from a typical patient sample, e.g.,
0.5mL, if the goal is to isolate subsequently CNS-derived
exosomes for biomarker analysis. Therefore, we focus here on
isolation methods that have been used successfully for isolating
CNS-derived blood exosomes followed by biomarker analysis.
For more general reviews on exosome isolation techniques (see
Li et al., 2017; Doyle and Wang, 2019).
The use of blood plasma as a source of exosomes requires
the addition of EDTA or heparin to prevent clotting and
subsequent separation of plasma by centrifugation (e.g., 15min
at 2,500 g) (Goetzl et al., 2015). To isolate exosomes from human
plasma, thrombin needs to be added to the plasma samples
prior to proceeding with the actual isolation. Alternatively,
serum can be obtained by allowing the blood to clot for
15–20min at room temperature before separating the serum
by centrifugation and the serum then can be used directly
for exosome isolation. Addition of protease and phosphatase
inhibitors to the samples and maintaining the clotting time
consistent for all the samples under study is crucial for preventing
degradation or modification of exosomal ingredients, especially
those present in minute concentrations (Fiandaca et al., 2015;
Goetzl et al., 2015). Additional precautionary measures should be
taken for measurement of α-synuclein in CNS-derived exosomes
isolated from the blood as minute quantities of erythocytic α-
synuclein released upon hemolysis can contaminate the sample.
A side-by-side comparison of the protocols developed by the
two first groups pioneering this field, the Zhang and Goetzl
groups, is shown in Figure 3. The Zhang group was the first
to describe a method for isolating CNS-derived exosomes from
mouse and human plasma. Their approach used anti-L1CAM
antibodies immobilized on superparamagnetic microbeads for
immuno-capture of CNS-derived exosomes directly from plasma
diluted 1:3 in phosphate-buffered saline without prior isolation
of total exosomes (Figure 3A). They incubated diluted plasma
samples with anti-L1CAM antibody-coated epoxy beads for
24 h with gentle rotation before proceeding to exosome release
or lysis.
In the work of Goetzl and co-workers, the process included
an initial polymer-assisted precipitation of extracellular vesicles
from serum or plasma followed by immunoprecipitation using
antibodies specific for NCAM or L1CAM to enrich CNS
neuronal exosomes (Figure 3B; Fiandaca et al., 2015). They
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TABLE 2 | Selected publications analyzing biomarkers in CNS-derived blood exosomes.
Exosome isolation
method
Validation methods Study cohort Analyzed biomarkers Outcome References
Immunocapture using
anti-L1CAM
antibody-coated M-270
Dynabeads
TEM, Western blot PD: 267
HC: 215
Neuronal exosomal
α-synuclein
α-synuclein: PD↑,
Correlation with
disease severity
Shi et al., 2014
Exosome precipitation and
immunocapture using
biotinylated anti-NCAM or
anti-L1CAM antibodies and
streptavidin-agarose resin
NTA AD: 57
AC: 57
FTD: 16
FTC: 16
AD (preclinical and after AD
diagnosis): 24
Neuronal exosomal Aβ42,
total tau, pT181-tau,
pS396-tau
Aβ42, total-tau, pT181-tau,
pS396-tau: AD↑
Aβ42, pT181-tau: FTD↑
Aβ42, pT181-tau,
pS396-tau: Preclinical AD↑
compared to AC, AD↑
compared to preclinical AD
and AC
Fiandaca et al.,
2015
Exosome precipitation and
immunocapture using
biotinylated anti-L1CAM
antibody and
streptavidin-polyacrylamide
resin
NTA AD: 26
AC: 26
FTD: 16
FTC: 16
AD (preclinical and after AD
diagnosis): 20
Neuronal exosomal
Cathepsin D, LAMP-1,
Ubiquitin, HSP-70
Cathepsin D, LAMP-1,
ubiquitinylated proteins:
AD↑ compared to AC and
FTD
HSP70: AD↓ compared to
AC, FTD↓ compared to FTC
and AD
Cathepsin D: FTD↑
compared to FTC
Cathepsin D, LAMP-1,
ubiquitinylated proteins:
preclinical AD↑, AD↑
compared to AC
HSP70: preclinical AD↓,
AD↓ compared to AC
Goetzl et al., 2015
Exosome precipitation and
immunocapture using
biotinylated anti-L1CAM
antibody and
streptavidin-polyacrylamide
resin
TEM, NTA AD: 10
MCI: 20
MCI to AD converter: 20
HC: 10
Neuronal exosomal Aβ42,
pT181-tau, pS396-tau
Aβ42, pT181-tau,
pS396-tau: AD↑, MCI to AD
converter↑ both compared
to MCI and HC
NRGN, REST: AD↓, MCI to
AD converter↓ both
compared to MCI and HC
Winston et al.,
2016
Exosome precipitation and
immunocapture by
biotinylated anti-GLAST or
anti-L1CAM antibodies and
streptavidin-agarose resin
NTA AD: 12
AC: 10
FTD: 14
FTC: 10
Neuronal and astrocytic
exosomal BACE-1,
γ-secretase, sAPPα, sAPPβ,
Septin-8, GDNF, Aβ42,
pT181-tau, pS396-tau
BACE-1, sAPPβ: AD↑, FTD
n.s.
GDNF: AD/MCI↓, FTD n.s.
BACE-1, γ-secretase, Aβ42,
sAPPα, sAPPβ, GDNF,
pT181-tau, pS396-tau: ADE
of all groups↑ compared
to NDE
Goetzl et al., 2016
Immunocapture using
anti-L1CAM
antibody-coated M-270
Dynabeads
TEM, Western Blot,
NTA
PD: 91
AD: 106
HC: 106
Neuronal exosomal total tau Total-tau: PD↑ compared to
AD and HC
Correlation to disease
duration and CSF tau in PD
Shi et al., 2016
Immunocapture using
anti-L1CAM
antibody-coated M-270
Dynabeads
Not determined Normosmia/ no DAT
reduction: 80
Hyposmia/ no DAT
reduction: 133
Hyposmia/ DAT
reduction: 43
Total plasma and neuronal
exosomal α-synuclein
Total-α-synuclein:
Hyposmic/ DAT reduction↑
at baseline and
longitudinally
NDE α-synuclein:
Hyposmic/ DAT reduction↓
longitudinally
Correlation with cognitive
function and DAT imaging
Wang et al., 2018
Exosome precipitation and
immunocapture by
biotinylated anti-L1CAM
antibody and
streptavidin-agarose resin
TEM PD: 39
HC: 40
Neuronal exosomal DJ-1
and α-synuclein
DJ-1 and α-synuclein: PD↑
compared to HC Zhao et al., 2019
(Continued)
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TABLE 2 | Selected publications analyzing biomarkers in CNS-derived blood exosomes.
Exosome isolation
method
Validation methods Study cohort Analyzed biomarkers Outcome References
Exosome precipitation and
immunocapture by
biotinylated anti-NCAM
antibody and
streptavidin-agarose resin
TEM, Western blot Discovery stage:
AD: 28
aMCI: 25
HC: 29
Validation stage:
AD: 73
aMCI: 71
HC: 72
Neuronal exosomal Aβ42,
total-tau, pT181 tau
Aβ42, total-tau, pT181-tau:
aMCI↑ compared to HC,
AD↑ compared to aMCI and
HC
Exosomal biomarker
correlate with respective
CSF biomarker
Jia et al., 2019
Exosome precipitation and
immunocapture by
biotinylated anti-L1CAM or
anti-GLAST antibodies
immobilized on
streptavidin-coated
magnetic beads
FACS mTBI: 19
HC: 20
Neuronal and astrocytic
exosomal Aβ40, Aβ42,
NRGN, NfL, total tau,
pT181-tau, pS396-tau
Aβ42: mTBI↑
NRGN: mTBI↓
Aβ40, total-tau, NfL,
pT181-tau, pS396-tau:
mTBI n.d. or n.s.
Winston et al.,
2019
↑, increased; ↓, decreased; AC, Alzheimer’s disease control; AD: Alzheimer‘s disease; ADE, astrocyte-derived exosomes; aMCI, amnestic mild cognitive impairment; Aβ40, amyloid
β-protein 1-40; Aβ42, amyloid β-protein 1-42; BACE-1, β-site amyloid precursor protein-cleaving enzyme 1; CSF, cerebrospinal fluid; DAT, dopamine transporter; FACS, fluorescence
activated cell sorting; FTC, frontotemporal dementia control; FTD: frontotemporal dementia; GDNF, glial-derived neurotrophic factor; GLAST, glutamate aspartate transporter; HC,
healthy control; HSP70, heat shock protein 70; L1CAM, L1-cell adhesion molecule; LAMP-1, lysosomal-associated membrane protein 1; MCI, mild cognitive impairment; MOG, myelin
oligodendrocyte glycoprotein; mTBI, mild traumatic brain injury; n.d., not detectable; n.s., not significant; NCAM, neuronal cell adhesion molecule; NDE, neuron-derived exosomes;
NfL, neurofilament light; NRGN, neurogranin; NTA, nanoparticles tracking analysis; PD, Parkinson‘s disease; pS396-tau, tau phosphorylated at S396; pT181-tau, tau phosphorylated
at T181; REST, repressor element 1-silencing transcription factor; sAPPα/β, soluble amyloid precursor protein α/β; TEM, transmission electron microscopy; TRPS, tunable resistive
pulse sensing.
first incubated serum or thromboplastin-D-treated plasma
samples with the non-specific PEG-based ExoQuick exosome
precipitation solution to obtain a pellet of total exosomes, which
was resuspended and the incubated with biotinylated anti-human
NCAM or L1CAM antibodies to enrich neuronal exosomes
by subsequent immunoprecipitation using a streptavidin-coated
polyacrylamide resin (Goetzl et al., 2015). Similar approaches
were used later by the groups of Kapogiannis, Rissman, and
others (Winston et al., 2016; Doyle and Wang, 2019).
After capturing the exosomes by antibody-coated beads,
according to both groups’ protocols the beads are washed
and the NCAM/L1CAM-positive exosomes can be eluted, e.g.,
for morphological analysis and for measurement of exosome
number and size using methods, such as Nanoparticle Tracking
Analysis (NTA), Tunable Resistive Pulse Sensing (TRPS) or
Microfluidic Resistive Pulse Sensing (MRPS) (Shi et al., 2014;
Goetzl et al., 2016; Winston et al., 2016; Jia et al., 2019; Yan
et al., 2019). Alternatively, the exosomes may be lysed on the
beads by treatment with different buffers, such as Mammalian
Protein Extraction Reagent (M-PER) (Fiandaca et al., 2015;
Goetzl et al., 2015) or other detergent-containing buffers for
different downstream analyses and biomarker measurement (Shi
et al., 2014, 2016; Wang et al., 2018). The methods used in
different studies and themeasured candidate biomarkers in CNS-
derived blood exosomes for different neurological diseases and
conditions are summarized in Table 2. The reported methods
for isolation of CNS-derived exosomes from blood samples
share wide similarities and differ mainly in the type of solid
support used to immobilize the respective antibodies in the
immunoprecipitation step. Although to date no study has
compared side-by-side the different approaches, the efficiency
and specificity of each method likely depends mainly on the
specificity of the used antibody.
Adaptations of the protocol of Goetzl et al. have subsequently
been applied for the isolation of astrocyte-derived blood
exosomes using an anti-GLutamate ASpartate Transporter
(GLAST) antibody (Goetzl et al., 2016, 2018). Our group
was the first to successfully isolate oligodendrocyte-derived
blood exosomes using anti-myelin oligodendrocyte glycoprotein
(MOG) antibody coupled to magnetic Dynabeads (Dutta et al.,
2018). A challenge in such studies is to confirm that the isolated
exosomes indeed originated in the cell type intended. Such
confirmation can be achieved using dot blots or western blots
using antibodies against specific protein markers of the cells of
origin. For example, enolase 2 or glutamate ionotropic receptor
AMPA type subunit 1 (GRIA1) may be used to identify neuronal
exosomes, glial fibrillary acidic protein (GFAP) for astrocytic
exosomes, and myelin proteolipid protein for oligodendroglial
exosomes. The challenge in such experiments is due to the low
abundance of exosomes released specifically from these cell types
into the blood (Doyle and Wang, 2019), which in our experience
is ≤1% of the total serum/plasma exosomes. To address this
challenge one must either isolate the exosomes starting with
relatively large starting volumes of serum/plasma or use detection
methods with higher sensitivity than those of dot blots or
western blots.
It is also important to note that immunoprecipitation
using NCAM or L1CAM does not provide exclusively CNS
neuronal exosomes. NCAM and L1CAM are enriched in, but
are not restricted to, neurons. They also may be present
in microvesicles other than exosomes though no information
exists currently regarding this possibility. According to the
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FIGURE 3 | Isolation of CNS-derived exosomes from blood. (A) The protocol of the Zhang group relies on anti-L1CAM antibody-coupled epoxy beads, which are
incubated directly with diluted plasma to bind neuronal exosomes. The following washing steps in 0.1% BSA remove unbound, non-neuronal exosomes in the
sample. (B) The method described by Goetzl et al. The protocol uses first an exosome precipitation step by ExoQuick followed by capturing specifically neuronal
exosomes with biotinylated anti-L1CAM antibodies and a streptavidin-conjugated resin. Subsequent washing steps remove non-neuronal exosomes as well as the
antibody and resin to yield neuronal exosomes.
human protein atlas (https://www.proteinatlas.org), L1CAM
is expressed mainly in the CNS, peripheral nervous system
(PNS), and in distal renal tubules whereas NCAM is mainly
observed in the CNS, PNS, adrenal gland, heart, and peptic
cells. Proteomic analysis of L1CAM-captured exosomes from
plasma showed higher concentrations of several CNS marker
proteins, including phosphorylated tau, neuron-specific enolase,
microtubule associated protein 2, neurofilament light chain
(NfL), and L1CAM than in total exosome samples (i.e., before
enrichment of neuronal exosomes) (Mustapic et al., 2017),
suggesting that the majority of the exosomes indeed originated in
CNS neurons. Nonetheless, the field should continue searching
for, and testing, more specific markers that will allow isolation of
purer exosome populations of CNS neurons and other cell types.
Moreover, as different neurological diseases affect different brain
regions, markers specific to a brain region or a neuron type, e.g.,
dopaminergic neurons for PD, may be developed in the future
and allow biomarker analysis that would offer higher level of
precision than general neuronal markers.
CURRENT CHALLENGES AND FUTURE
PERSPECTIVES
Extensive research in the last two decades has demonstrated
that exosomes play a role in both physiological and pathological
states of cells in the CNS. These vesicles function as intercellular
communicators and serve as a vehicle for disposal of unwanted
biological material. By carrying aggregated amyloidogenic
proteins from cell to cell, exosomes contribute to the spread
of these pathologic proteoforms in various neurodegenerative
disorders. Impairment of the lysosomal and/or proteasomal
pathways has been reported to increase disposal of pathogenic
proteins via exosomes, contributing to disease spread in the CNS.
However, the mechanisms involved in this process, the uptake of
the released exosomes by specific recipient cells, the involvement
of receptors and the impact of the lipid composition in the
exosome membrane in these processes are yet to be elucidated.
Numerous studies have examined biofluid biomarkers for
neurodegenerative diseases (Table 1). In AD, the most consistent
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biomarkers have been Aβ42, total tau, pT181-tau, and pS396-
tau measured in CSF and more recently in neuronal exosomes
(Tapiola et al., 2009; Fiandaca et al., 2015; Goetzl et al., 2016;
Winston et al., 2016; Jia et al., 2019). The same biomarker
panel has been shown to distinguish FTD from AD and
healthy controls in multiple studies mostly using CSF as a
biomarker source. In addition, although NfL is elevated in most
neurodegenerative diseases, it was found to be significantly
higher in FTD than in AD (Irwin et al., 2013; Fiandaca et al.,
2015; Abu-Rumeileh et al., 2018; Goossens et al., 2018). DJ-1
and α-synuclein have been shown to be promising biomarkers
in the diagnosis of PD. Results from studies involving neuronal
exosomes have been demonstrated to be reproducible for α-
synuclein (Shi et al., 2014; Dutta et al., 2018; Zhao et al., 2019)
and for different forms of Aβ and tau (Fiandaca et al., 2015;
Goetzl et al., 2016; Winston et al., 2016; Jia et al., 2019), and
the acquired data in the neuronal exosomes correlated to those
obtained from CSF samples (Jia et al., 2019). Increased CSF
levels of tau and 14-3-3 proteins and decreased concentration
levels of total PrP were found to be potential biomarkers for
prion diseases (Otto et al., 1997; Llorens et al., 2018). NfL and
phosphorylated forms of the neurofilament heavy chain have
been shown consistently to be increased in the CSF, plasma,
and serum of patients with ALS in several single- and multi-
center studies (Boylan et al., 2013; Lehnert et al., 2014; Lu et al.,
2015; Oeckl et al., 2016). However, NfL is associated with many
neurodegenerative diseases and is likely to be more useful as an
indicator of disease progression rather than diagnosis (Olsson
et al., 2019; Preische et al., 2019). Therefore, TDP-43 measured
in CSF may constitute a more promising biomarker for ALS
as it was demonstrated to be a main component in the disease
pathology (Neumann et al., 2006) and its concentration levels
are elevated in patients with ALS compared to healthy controls
(Kasai et al., 2009) and patients of other neurodegenerative or
inflammatory diseases (Table 1; Noto et al., 2011; Hosokawa
et al., 2014). Nevertheless, there is still a need for more
specific biomarkers obtained through minimally invasive means
for diagnosing patients reliably, ideally in early disease stages,
monitor their disease progression, and evaluate clinical-trial
outcomes. Similar needs exist for many rare neurodegenerative
and neuromuscular diseases, many of which are genetic (e.g.,
ataxias, myotonic dystrophies) and can be diagnosed based
on identifying the relevant mutant gene, but without reliable
progression biomarkers, conducting successful clinical trials is
a major challenge. Investigating new sources, such as CNS-
derived exosomes, promises to generate robust biomarkers for
neurodegenerative diseases through simple blood tests.
CNS-derived exosomes isolated from blood also have been
shown to be a useful source of biomarkers for other neurological
conditions, including stroke (Chen et al., 2016) and TBI (Winston
et al., 2019), and for following brain processes that are not
easily accessible, such as adult hippocampal neurogenesis (AHN)
(Luarte et al., 2017). The enrichment of exosomes derived
from specific brain cell types, such as neurons, astrocytes, and
recently oligodendrocytes by immuno-capture likely will provide
a more specific and useful source of diagnostic and progression
biomarkers compared to plasma or serum themselves or total
exosomes isolated from these biofluids. The fourth brain-cell
type, microglia, presents a unique challenge because microglia
share surface markers, which potentially could be used to
distinguish their exosomes from the other brain-cell types, with
peripheral monocytes and macrophages. In the absence of a
unique microglial marker presented on the exosomal membrane,
isolation of microglial exosomes from blood currently is
not possible.
An important practical challenge in the methodology
discussed above is the limited sample volume typically available
from biobanks or providing clinics and the minute number of
CNS-derived exosomes in such samples, necessitating the use
of high-sensitivity detection methods, such as single molecule
array (SIMOA, Quanterix, USA), electrochemiluminescence
ELISA (Meso Scale Discovery, USA) or Immuno magnetic
reduction (MagQu, Taiwan). Another potential difficulty,
discussed more in personal communication than represented
in the published literature, is the reproducibility of biomarker
analysis in CNS-derived exosomes. The challenges are both
the exosome-isolation process itself, which requires a high
level of expertise and precision, and the characterization of
the subsequent assays, which must be done for each assay
separately using multiple independent exosome preparations for
establishing acceptable intra- and inter-experiment coefficients
of variation. There is still a need for reproducible, standardized
protocols for isolation of exosomes and subsequent analysis
of biomarkers of interest. Nonetheless, the examples discussed
above demonstrate that exosome populations enriched from
specific brain cell-types hold potential as a promising source
of biomarkers for different neurodegenerative disorders and
it will be particularly interesting to compare biomarkers in
exosomes from different cell types side-by-side in the same
samples. Finally, a major difficulty specific for development
of diagnostic biomarkers for many neurodegenerative diseases
is the absence of samples from patients with a validated
diagnosis. To develop this field further, the establishment of
biobanks containing pathologically validated samples from
patients with neurodegenerative diseases and healthy controls
is essential.
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